

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov

June 10, 2020

#### SUBSTANTIALLY EQUIVALENT

Republic Tobacco, LP Attention: Carl Ioos, Senior Vice President 2301 Ravine Way Glenview, IL 60025

# FDA Submission Tracking Numbers (STNs): Multiple STNs, see Appendix A

Dear Mr. loos:

We completed our review of your SE Reports<sup>1</sup> and determined that the new tobacco products are substantially equivalent to the corresponding predicate tobacco products listed in Appendix A and are in compliance with the requirements of the FD&C Act. Under the provisions of section 910 and 905(j) of the FD&C Act, you may introduce or deliver for introduction into interstate commerce the new tobacco products subject of this letter.

Our finding does <u>not</u> mean we "approved" the new products specified in Appendix A; therefore, you may not promote or in any way represent the new tobacco products specified in Appendix A, or the labeling, as being "approved" by FDA (see Section 301(tt) of the FD&C Act).

For information on how to fulfill the provisions of section 910(a)(4) of the FD&C Act, refer to Appendix B.

In accordance with 40 CFR 1506.6, we will make your Environmental Assessment (EA) publicly available.

All regulated tobacco products, including the tobacco products specified in Appendix A, are subject to the requirements of the FD&C Act and its implementing regulations. It is your responsibility to ensure the tobacco products specified in Appendix A comply with all applicable statutory and regulatory requirements. FDA will monitor your compliance with all applicable statutes and regulations.

If you have any questions, please contact Fredris Wiley, Regulatory Health Project Manager, at (301) 348-1499 or Fredris.Wiley@fda.hhs.gov.

Sincerely,

Digitally signed by Glen D. Jones -S Date: 2020.06.10 11:47:56 -04'00'

For Matthew R. Holman, Ph.D. Director Office of Science Center for Tobacco Products

**Enclosures:** 

Appendix A – New and Corresponding Predicate Tobacco Products Subject of This Letter Appendix B – Health Information Summary

<sup>&</sup>lt;sup>1</sup> Substantially Equivalent (SE) Reports submitted under section 905(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

New and Corresponding Predicate Tobacco Products Subject of This Letter		
Common Attributes of SE Reports		
Date of Submission:	March 5, 2020	
Date of Receipt:	March 5, 2020	
Product Manufacturer:	Republic Technologies Canada	
Product Category:	Roll-Your-Own Tobacco Products	
Product Sub-Category:	Filtered Cigarette Tube	
	New Tobacco Product Specific	Predicate Tobacco Product Specific
	Attributes	Attributes
	SE0015755: Bull Durham Blue	GF1908299: TOP Light 100MM Tubes <sup>2</sup>
	100MM <sup>2</sup>	
Package Type:	Box	Box
Package Quantity:	200 Tubes	200 Tubes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Grandfathered
Length:	100 mm	100 mm
Diameter:	8.2 mm	8.2 mm
Ventilation:	None	None
	New Tobacco Product Specific	Predicate Tobacco Product Specific
	Attributes	Attributes
	SE0015756: Bull Durham Regular King	N/A: Gambler Regular King Size <sup>2</sup>
	Size <sup>2</sup>	
Package Type:	Box	Box
Package Quantity:	200 Tubes	200 Tubes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Grandfathered
Length:	84 mm	84 mm
Diameter:	8.2 mm	8.2 mm
Ventilation:	None	None

# Appendix A

New and Corresponding Predicate Tobacco Products Subject of This Letter

<sup>&</sup>lt;sup>2</sup> Brand/sub-brand or other commercial name used in commercial distribution.

# Appendix B

# Health Information Summary

Your SE Reports did not provide a summary of any health information related to the new tobacco products, required by section 910(a)(4) of the FD&C Act; however, your SE Reports stated that such information will be available upon request to any person. Consistent with the requirements of section 910(a)(4), you may wish to consider providing the following when information is requested:

- A. A copy of your final SE Reports upon which the Substantially Equivalent order was based, redacted only to the extent necessary to exclude patient identifiers and trade secret and confidential commercial information as defined in 21 CFR 20.61 and 20.63.
- B. Any research or data you have in your possession or otherwise know of specifically regarding the adverse health effects of the new tobacco products, or the following statement if such statement is accurate: "[Insert manufacturer name] does not have or know of any research or data regarding any adverse health effects specifically related to [insert tobacco product name]."

Alternatively, you may provide the following when information is requested:

Description of the new tobacco products

Description of the predicate tobacco products

List of all differences in characteristics between the new and predicate tobacco products Summary of the evidence and scientific rationale concerning why the differences in characteristics do not raise different questions of public health

Any research or data you have in your possession or otherwise know of regarding the adverse health effects of the new tobacco product, or the following statement if such statement is accurate: "[Insert manufacturer name] does not have or know of any research or data regarding any adverse health effects specifically related to [insert tobacco product name]."

There may be other accurate, complete, and not false or misleading ways to satisfy the requirements of section 910(a)(4) not included above. If you wish to discuss other ways to meet the requirements of section 910(a)(4), submit a meeting request to us.